Technology | Proton Therapy | August 18, 2016

ProteusONE is the first FDA cleared and CE marked compact solution using image guided IMPT

ProteusONE, IBA, FDA approval, FDA clearance of ProteusONE, compact proton therapy
ProteusONE, IBA, FDA approval, FDA clearance of ProteusONE, compact proton therapy

A room layout for the IBA ProteusOne compact proton therapy system.


August 18, 2016 — IBA (Ion Beam Applications SA) has received U.S. Food and Drug Administration (FDA) clearance for its new super conducting accelerator, which is the latest development, essential to the ProteusONE compact Intensity Modulated Proton Therapy (IMPT) solution, that required approval from regulatory authorities. 

The FDA clearance makes ProteusONE, the only compact proton therapy solution in the industry, that is certified to treat patients in the United States with optimized pencil beam scanning (PBS) and image guidance.
 
IBA has already signed 13 contracts to provide its compact proton therapy solution worldwide. The FDA clearance is an important milestone that will ensure on-time delivery of all of IBA’s current and future contracts.
 
“FDA clearance of our ProteusONE's new super conducting accelerator will be a significant market accelerator for proton therapy in the United States, because ProteusONE provides the most advanced treatment mode within the most compact and affordable system,” said Beth Klein, president of IBA Proton Therapy North America. “Any hospital considering proton therapy can now afford it through the ProteusONE’s lower capital and operating costs without making any clinical compromise. Ultimately, this will make proton therapy more accessible to the radiation therapy patients in the United States who can benefit from it.”
 
The ProteusONE is the world’s only FDA cleared and CE marked compact solution that uses image guided IMPT. With IBA’s industrialized production together with full CE approval and FDA clearance, IBA is now able to install complete proton therapy system in less than 12 months.
 
The ProteusONE is equipped with pencil beam scanning, a technology that offers high sub-millimeter precision treatment, which allows delivery of very high levels of conformity and dose uniformity, even in complex-shaped tumors, whilst at the same time sparing the surrounding healthy tissue.
 
For more information: www.iba-worldwide.com

Related Content

Videos | Radiation Therapy

Jeffrey T. Chapman, a medical student at the University of Texas Southwestern Medical Center, Explains how watching ...

Time November 24, 2021
arrow
News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
News | Lung Imaging

November 19, 2021 — Lung cancer screening is recommended only for those who are at high risk for the disease — adults ...

Time November 19, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 ...

Time November 18, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
Videos | Radiation Therapy

The Elekta Harmony radiotherapy system gained FDA clearance in the summer of 2021 and was on display for the first time ...

Time November 17, 2021
arrow
News | Radiation Therapy

November 17, 2021 — Radiation can be a powerful cancer therapy, but it doesn’t work for everyone. A new study identifies ...

Time November 17, 2021
arrow
Videos | Radiation Oncology

This is a model of the Toshiba ion beam radiation therapy system at the American Society of Radiation Oncology (ASTRO) ...

Time November 16, 2021
arrow
News | Breast Imaging

November 16, 2021 — Patients with two out of the three most common types of advanced breast cancer now have an average ...

Time November 16, 2021
arrow
News | Prostate Cancer

November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 ...

Time November 16, 2021
arrow
Subscribe Now